Skip to content
4271cc84 1a9d 4105 8bd7 f637c87885c2 | Quentinvest
Subscribers Only
Investment Alerts

Immunotherapy shares spring to life

May 28, 2020

Allogene Therapeutics describes what it is doing as "The next revolution in cell therapy." In more detail they describe themselves as "a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer."

Below are quotes from a recent market report describing a sharp jump in the Allogene share price.

To continue reading this article...

Subscribe

Already a subscriber?

Further reading

More >
iStock 1473420344 | Quentinvest
Subscribers Only
Investment Alerts

Barclays Walks a Stock Chart Tightrope

March 24, 2023
iStock 606003002 | Quentinvest
Subscribers Only
Investment Alerts

Pros and Cons of Big Picture Share Trading Indicators

March 23, 2023
iStock 1307254034 | Quentinvest
Subscribers Only
Investment Alerts

Bitcoin at $1 Million – Why Not?

March 22, 2023
iStock 1270263286 | Quentinvest
Subscribers Only
Investment Alerts

Artificial Intelligence Revolution: 3 Companies That Will Benefit

March 21, 2023